|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
[A34450921]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1Á¤(2001.06.01)(ÇöÀç¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
´ÙÀ½ ÁúȯÀÇ ±âµµÆó¼â¼º Àå¾Ö¿¡ ÀÇÇÑ È£Èí°ï¶õ µî ¿©·¯ Áõ»óÀÇ ¿ÏÈ : ±â°üÁöõ½Ä
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¼ºÀÎ : Æä³ëÅ׷Ѻê·Òȼö¼Ò»ê¿°À¸·Î¼ 1ȸ 2.5 mgÀ» 1ÀÏ 3ȸ °æ±¸Åõ¿©ÇÑ´Ù.
|
| ±Ý±â |
1) ±³°¨½Å°æ ÈïºÐ¼º ¾Æ¹Î·ù¿¡ °ú¹Î¹ÝÀÀÀÇ º´·ÂÀÌ Àִ ȯÀÚ
2) ºñÈļº Æó¼â¼º ½É±Ùº´Áõ ȯÀÚ
3) ºÎÁ¤ºó¸Æ ȯÀÚ
4) ÀÌ ¾à ¶Ç´Â ÀÌ ¾àÀÇ ±¸¼º¼ººÐ¿¡ °ú¹Î¹ÝÀÀÀÌ Àִ ȯÀÚ |
| ½ÅÁßÅõ¿© |
1) °©»ó¼±±â´ÉÇ×ÁøÁõ ȯÀÚ
2) °íÇ÷¾Ð ȯÀÚ
3) ½ÉºÎÀüÁõ, ºÎÁ¤¸Æ µî ½ÉÁúȯ ȯÀÚ
4) ´ç´¢º´ ȯÀÚ
5) °í·ÉÀÚ |
| ÀÌ»ó¹ÝÀÀ |
´Ù¸¥ º£Å¸-È¿´ÉÁ¦¿Í ¸¶Âù°¡Áö·Î ÀÌ ¾àÀº ÁßÁõÀÇ ÀúÄ®·ýÇ÷ÁõÀ» Æ÷ÇÔÇÑ ´ÙÀ½°ú °°Àº ÀÌ»ó¹ÝÀÀÀ» À¯¹ßÇÒ ¼ö ÀÖ´Ù.
1) ¸é¿ª±â°è : °ú¹Î¹ÝÀÀ(¹ßÁø, °¡·Á¿ò, µÎµå·¯±â)ÀÌ ³ªÅ¸´Â °æ¿ì Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
2) ´ë»ç ¹× ¿µ¾çÀå¾Ö : ÀúÄ®·ýÇ÷Áõ
3) Á¤½Å°è : ÃÊÁ¶, ½Å°æ°ú¹Î
4) ½Å°æ°è : ÁøÀü, µÎÅë, ¾îÁö·³, Á¹À½, ºÒ¸é
5) ½ÉÇ÷°ü°è : ½É±ÙÇãÇ÷, ºó¸Æ(ºü¸¥¸Æ), ½É°èÇ×Áø(µÎ±Ù°Å¸²), Ç÷¾Ðº¯µ¿, ºÎÁ¤¸Æ, °íÇ÷¾Ð, ¾ó±¼ÀÌ È²ö°Å¸², ÈäÅë
6) È£Èí±â°è : ±âħ, ±â°üÁö¿°, õ¸í, Àεο°, ºñÃæÇ÷
7) À§Àå°ü°è : ±¸¿ª, ±¸Åä, ½Ä¿åºÎÁø, ¼ÒȺҷ®, ±¸°¥, º¹Åë, À§ºÎºÒÄè°¨, º¯ºñ
8) ÇǺΠ¹× ÇÇÇÏÁ¶Á÷ : ´ÙÇÑÁõ, ¹ßÁø, °¡·Á¿ò, µÎµå·¯±â¿Í °°Àº ÇǺιÝÀÀ
9) ±Ù°ñ°Ý°è, °áÇÕÁ¶Á÷, »À : ±ÙÀ°¿¬Ãà, ±ÙÀ°Åë, ±ÙÀ°¼è¾à
10) °Ë»ç : ¼öÃà±âÇ÷¾Ð Áõ°¡, È®Àå±âÇ÷¾Ð °¨¼Ò
11) °ú¹Î¹ÝÀÀ : ¸Å¿ì µå¹°°Ô Ç÷°üºÎÁ¾, ±â°üÁö°æ·Ã, ±¸° ÀεκÎÁ¾, ÀúÇ÷¾Ð, ÇãÅ» µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç ÀÌ·¯ÇÑ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
12) ±âŸ : µå¹°°Ô ±¸³»¿°, ±Çۨ, ¼öÁöÁ¾Ã¢°¨
|
| »óÈ£ÀÛ¿ë |
1) ÀÌ ¾àÀ» ¿¡Çdz×ÇÁ¸°, À̼ÒÇÁ·ÎÅ×·¹³î µîÀÇ Ä«Å×Äݾƹηù¿Í º´¿ëÇÏ¸é ºÎÁ¤¸Æ ¶Ç´Â ½ÉÁ¤Áö¸¦ ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î º´¿ëÅõ¿©ÇÏÁö ¾Ê´Â´Ù.
2) MAO¾ïÁ¦Á¦³ª »ïȯ°è Ç׿ì¿ïÁ¦·Î Ä¡·áÁßÀΠȯÀÚ¿¡°Ô ÀÌ ¾àÀ» Åõ¿©Çϸé ÀÌ ¾àÀÇ Ç÷°ü°è¿¡ ´ëÇÑ ÀÛ¿ëÀÌ Áõ°¡µÉ ¼ö ÀÖÀ¸¹Ç·Î ƯÈ÷ ÁÖÀÇÇÑ´Ù.
3) ÀÌ ¾àÀ» ÇÁ·ÎÇÁ¶ó³î·Ñ µîÀÇ ºñ¼±ÅÃÀû º£Å¸Â÷´ÜÁ¦¿Í º´¿ëÅõ¿©ÇÏÁö ¾Ê´Â´Ù.
4) ´Ù·®ÀÇ ´Ù¸¥ ±³°¨½Å°æÈïºÐÁ¦¸¦ Åõ¿© ¹Þ°í Àִ ȯÀÚ¿¡°Ô ÀÌ ¾àÀ» Åõ¿© ½Ã¿¡´Â ÁÖÀÇÇÑ´Ù.
5) º£Å¸-¾Æµå·¹³¯¸°¼º¾à, Ç×Äݸ°ÀÛ¿ëÁ¦, ÀÜÆ¾À¯µµÃ¼(¿¹, Å׿ÀÇʸ°) ¹× ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å´Â ÀÌ ¾àÀÇ È¿°ú¸¦ Áõ°½Ãų ¼ö ÀÖ´Ù. ´Ù¸¥ º£Å¸-À¯»çÁ¦, Àü½Å Èí¼öµÇ´Â Ç×Äݸ°ÀÛ¿ëÁ¦ ¹× ÀÜÆ¾À¯µµÃ¼¿ÍÀÇ º´¿ëÅõ¿©´Â ÀÌ»ó¹ÝÀÀÀ» Áõ°¡½Ãų ¼ö ÀÖ´Ù.
6) ÀáÀçÀû Áß´ëÇÑ È¿°ú°¨¼Ò°¡ º£Å¸Â÷´ÜÁ¦¿Í º´¿ëÅõ¿© Áß¿¡ ¹ß»ýÇÒ ¼ö ÀÖ´Ù.
7) MAO¾ïÁ¦Á¦ ¶Ç´Â »ïȯ°èÇ׿ì¿ïÁ¦ Ä¡·á¸¦ ¹Þ°í Àִ ȯÀÚ¿¡°Ô º£Å¸-¾Æµå·¹³¯¸°¼º È¿´ÉÁ¦¸¦ Åõ¿©½Ã¿¡´Â º£Å¸-¾Æµå·¹³¯¸°¼º È¿´ÉÁ¦ÀÇ ÀÛ¿ëÀÌ Áõ°µÉ ¼ö ÀÖÀ¸¹Ç·Î ¹Ýµå½Ã ÁÖÀǸ¦ ±â¿ï¿©¾ß ÇÑ´Ù.
8) ÇÒ·Îź, Æ®¸®Å¬·Î·Î¿¡Æ¿·»°ú ¿£Ç÷ç¶õ°ú °°Àº ÇҷΰÕÈµÈ ÅºÈ¼ö¼Ò ¸¶ÃëÁ¦´Â º£Å¸-È¿´ÉÁ¦ÀÇ ½ÉÇ÷°üÀÛ¿ë¿¡ ´ëÇÑ °¨¼ö¼ºÀ» Áõ°¡½Ãų ¼ö ÀÖ´Ù. |
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Fenoterol¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Beta(2)-receptor stimulation in the lung causes relaxation of bronchial smooth muscle, bronchodilation, and increased bronchial airflow.
|
| Pharmacology |
Fenoterol¿¡ ´ëÇÑ Pharmacology Á¤º¸ Fenoterol is a beta agonist designed to open up the airways to the lungs.
|
| Pharmacokinetics |
Fenoterol HBrÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : ÈíÀÔ ¶Ç´Â °æ±¸Åõ¿©½Ã ½Å¼ÓÇÏÁö¸¸ ºÒ¿ÏÀüÇÏ°Ô Èí¼öµÊ.
- ÃÖ°íÈ¿°ú ¹ßÇö½Ã°£
- °æ±¸ ÈíÀÔ : 10-15ºÐ
- °æ±¸ : 1-2 ½Ã°£
- ÀÛ¿ëÁö¼Ó½Ã°£ : 6½Ã°£
- ´ë»ç : ÃÊȸÅë°úÈ¿°ú Å. °£¿¡¼ ºñȰ¼ºÇü sulfate·Î ´ë»çµÊ.
- ¹Ý°¨±â : 6-7 ½Ã°£
- ¼Ò½Ç
- °æ±¸ Åõ¿©½Ã : ¾à 40%°¡ ´ëº¯À¸·Î ¹è¼³µÇ¸ç, 24½Ã°£ µ¿¾È¿¡´Â ¾à 35%°¡ ´ë»çü·Î, 2% ¹Ì¸¸ÀÌ ¹Ìº¯Èü·Î¼ ´¢¸¦ ÅëÇØ ¹è¼³µÊ.
|
| Biotransformation |
Fenoterol¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic.
|
| Toxicity |
Fenoterol¿¡ ´ëÇÑ Toxicity Á¤º¸ Symptoms of overdose include angina (chest pain), dizziness, dry mouth, fatigue, flu-like symptoms, headache, heart irregularities, high or low blood pressure, high blood sugar, insomnia, muscle cramps, nausea, nervousness, rapid heartbeat, seizures, and tremor.
|
| Drug Interactions |
Fenoterol¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Acebutolol AntagonismAlseroxylon Increased arterial pressureAmitriptyline The tricyclic increases the sympathomimetic effectAmoxapine The tricyclic increases the sympathomimetic effectAtenolol AntagonismBetaxolol AntagonismBevantolol AntagonismBisoprolol AntagonismCarteolol AntagonismCarvedilol AntagonismClomipramine The tricyclic increases the sympathomimetic effectDesipramine The tricyclic increases the sympathomimetic effectDeserpidine Increased arterial pressureDoxepin The tricyclic increases the sympathomimetic effectEsmolol AntagonismImipramine The tricyclic increases the sympathomimetic effectIsocarboxazid Increased arterial pressureLabetalol AntagonismLinezolid Possible increase of arterial pressureMethyldopa Increased arterial pressureMetoprolol AntagonismMidodrine Increased arterial pressureMoclobemide Moclobemide increases the sympathomimetic effectNadolol AntagonismNortriptyline The tricyclic increases the sympathomimetic effectOxprenolol AntagonismPargyline Increased arterial pressureProtriptyline The tricyclic increases the sympathomimetic effectTrimipramine The tricyclic increases the sympathomimetic effectPenbutolol AntagonismPractolol AntagonismPhenelzine Increased arterial pressurePindolol AntagonismPropranolol AntagonismSotalol AntagonismTimolol AntagonismRasagiline Increased arterial pressureReserpine Increased arterial pressureTranylcypromine Increased arterial pressure
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Fenoterol¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take without regard to meals.
|
| Drug Target |
[Drug Target]
|
| Description |
Fenoterol¿¡ ´ëÇÑ Description Á¤º¸ An adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic. [PubChem]
|
| Drug Category |
Fenoterol¿¡ ´ëÇÑ Drug_Category Á¤º¸ Adrenergic beta-AgonistsBronchodilator AgentsSympathomimeticsTocolytic Agents
|
| Smiles String Canonical |
Fenoterol¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1
|
| Smiles String Isomeric |
Fenoterol¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ C[C@H](CC1=CC=C(O)C=C1)NC[C@H](O)C1=CC(O)=CC(O)=C1
|
| InChI Identifier |
Fenoterol¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C17H21NO4/c1-11(6-12-2-4-14(19)5-3-12)18-10-17(22)13-7-15(20)9-16(21)8-13/h2-5,7-9,11,17-22H,6,10H2,1H3
|
| Chemical IUPAC Name |
Fenoterol¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 5-[1-hydroxy-2-[1-(4-hydroxyphenyl)propan-2-ylamino]ethyl]benzene-1,3-diol
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2024-10-29
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|